Gefticip 250mg Tablet 30’s

1. Product Introduction

Gefticip 250mg Tablet is an oral anticancer medication that contains the active ingredient Gefitinib, a targeted therapy classified under epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This medicine is used to treat non-small cell lung cancer (NSCLC) in patients with specific genetic mutations.

Gefitinib works by blocking the signals from the EGFR protein that promote the growth of cancer cells. By inhibiting this pathway, the medicine slows down or stops the multiplication of cancer cells, thereby controlling the spread of the disease.

Manufactured by Cipla Ltd., Gefticip 250mg Tablet is a vital option for patients who test positive for EGFR mutations and are not suited for traditional chemotherapy. It is usually taken once daily and must be used under strict medical supervision.

2. Uses of Gefticip 250mg Tablet

Gefticip is primarily used to treat:

• Non-Small Cell Lung Cancer (NSCLC) – Especially in patients whose cancer has spread to other parts of the body (metastatic) and who have tested positive for EGFR mutations.

Doctors may also prescribe this medicine for other off-label cancer treatments based on genetic testing and clinical indications.

3. Benefits of Gefticip 250mg Tablet

• Targeted Therapy: Gefitinib specifically targets cancer cells that express mutations in the EGFR gene, ensuring maximum efficacy with fewer side effects compared to conventional chemotherapy.

• Improved Quality of Life: Patients often experience fewer complications, better symptom control (like less cough, breathlessness), and improved physical functioning while on Gefticip.

• Convenient Oral Administration: Taken as a tablet once a day, Gefticip offers a non-invasive treatment alternative to intravenous chemotherapy.

• Better Tolerability: Gefitinib generally causes fewer severe side effects, making it a preferred first-line treatment in many cases.

• Delays Disease Progression: In EGFR-positive patients, Gefticip can significantly delay cancer progression, extending progression-free survival and sometimes even overall survival.

4. Side Effects

Like all medications, Gefticip 250mg Tablet may cause side effects. Most are manageable and reversible, but some can be serious and may require medical intervention.

Common Side Effects:

• Skin rash or acne

• Diarrhea

• Loss of appetite

• Weakness or fatigue

• Dry skin

• Nausea or vomiting

Serious Side Effects:

• Lung toxicity (Interstitial lung disease) – Symptoms include shortness of breath, persistent cough, and fever.

• Liver problems – Monitor with liver function tests.

• Eye problems – Blurred vision or eye pain.

• Gastrointestinal perforation – Extremely rare but serious.

Always report unusual or severe symptoms to your doctor immediately.

5. Frequently Asked Questions (FAQ)

Q1. What is Gefticip 250mg Tablet used for?
A: Gefticip is used for the treatment of non-small cell lung cancer (NSCLC) that has specific EGFR gene mutations. It is often used in cases where cancer has spread or cannot be surgically removed.

Q2. How should I take this medicine?
A: Take Gefticip exactly as prescribed by your doctor. It is usually taken once daily, with or without food. Swallow the tablet whole with water—do not crush or chew it.

Q3. Can I stop taking Gefticip if I feel better?
A: No. Even if symptoms improve, it is important to continue taking the medicine as prescribed. Stopping the treatment early can allow cancer to return or progress.

Q4. Can Gefticip be used with other cancer therapies?
A: In some cases, doctors may combine Gefticip with other therapies such as radiation or chemotherapy. This depends on the stage of cancer and the patient’s overall health condition.

Q5. Do I need any special tests before starting Gefticip?
A: Yes. A test to detect EGFR gene mutations is essential before starting therapy, as the effectiveness of Gefitinib depends on this mutation.